Kathy T. Wynne

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

Raj K. Maturi, Adam R. Glassman, Kristin Josic et al. · JAMA · 2023 · 60 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

Lee M. Jampol, Adam R. Glassman, Danni Liu et al. · Ophthalmology · 2018 · 44 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +12

Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema

David W. Hutton, Adam R. Glassman, Danni Liu et al. · JAMA Ophthalmology · 2023 · 24 citations · Full text

Medicine, Ophthalmology, Pharmacoeconomics +10

<p>Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)</p>

Jessica D. McCluskey, Paul L. Kaufman, Kathy T. Wynne et al. · International Medical Case Reports Journal · 2019 · 11 citations · Full text

Medicine, Ophthalmology, Surgery +17